Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.92 |
| ▸ | CA1 | P00915 | 15/20 | 0.92 |
| ▸ | CA7 | P43166 | 3/20 | 0.92 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.92 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | CA5A | P35218 | 7/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonamide SCHEMBL7968093 | 1.00 | — | — | |
| Trifluoromethanesulfonamide SCHEMBL6602452 | 0.96 | — | — | |
| Trifluoromethanesulfonamide SCHEMBL130 | 0.96 | — | — | |
| Trifluoromethanesulfonamide SCHEMBL29042995 | 0.96 | CA2 (1.00) | CA2CA1CA7CA13CA9 | |
| Trifluoromethanesulfonamide SCHEMBL23573920 | 0.92 | — | — | |
| Trifluoromethanesulfonamide SCHEMBL25420199 | 0.92 | CA2 (0.92) | CA2CA1CA7CA13CA9 | |
| Trifluoromethanesulfonamide SCHEMBL25437159 | 0.92 | CA2 (0.92) | CA2CA1CA7CA13CA9 | |
| Trifluoromethanesulfonamide SCHEMBL16714097 | 0.92 | CA2 (0.92) | CA2CA1CA7CA13CA9 | |
| Trifluoromethanesulfonamide SCHEMBL186798 | 0.92 | — | — | |
| Trifluoromethanesulfonamide SCHEMBL25437849 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778661-B1 | PROCESS FOR THE MANUFACTURE OF CHROMAN DERIVATIVES, ESPECIALLY ALPHA-TOCOPHEROL AND ALKANOATES THEREOF | DSM IP ASSETS BV (NL) | 2014-01-22 | — | — | EP | disclosed |
| US-8431727-B2 | Process for the manufacture of chroman derivatives, especially α-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2013-04-30 | — | — | US | disclosed |
| US-20090176998-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2009-07-09 | — | — | US | disclosed |
| US-20050277777-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alkanoates thereof | BONRATH WERNER | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277777-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alkanoates thereof | TTPA, TCP1, TST | CA2 1219/4885CA1 1354/4885CA7 1776/4885 |
| US-20090176998-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof | TTPA, TCP1, TBL2 | CA2 1040/4885CA1 1735/4885CA7 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.